NovaBridge Biosciences is a high-risk biotech focused on advancing its lead drug, Givastomig, which showed promising Phase 1b results with a 75% response rate and manageable safety in gastric cancer. The company reported a loss in FY25 but holds $210.8 million in cash, providing financial stability through 2028 to support ongoing clinical trials. Key upcoming milestones include Phase 1b data readouts in 2026 and potential accelerated approval, which could significantly impact the company's valuation. Investors should watch these catalysts closely as they may drive re-rating of the stock.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Peter Schiff, seorang kritikus Bitcoin, menyarankan investor untuk menjual kepemilikan BTC mereka di atas $60.000, memperingatkan potensi kerugian besar. Meskipun Bitcoin baru-baru ini naik 11% di bulan Juli, beberapa analis khawatir bahwa pemulihan ...
